Edition:
United Kingdom

Recordati Industria Chimica e Farmaceutica SpA (RECI.MI)

RECI.MI on Milan Stock Exchange

34.16EUR
21 Jun 2018
Change (% chg)

-- (--)
Prev Close
€34.16
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
873,560
52-wk High
€40.80
52-wk Low
€27.49

Latest Key Developments (Source: Significant Developments)

Fimei Confirms Negotiations With CVC For Sale Of Recordati By Recordati Family
Wednesday, 20 Jun 2018 

June 20 (Reuters) - Recordati Industria Chimica e Farmaceutica SpA ::FIMEI CONFIRMS THAT THERE ARE NEGOTIATIONS WITH CVC FUND FOR SALE BY RECORDATI FAMILY OF INDIRECT CONTROL OF RECORDATI.FIMEI ADDS THERE ARE 'MANY' OBSTACLES TO OVERCOME AND THERE IS NO CERTAINTY OVER PROSECUTION OF NEGOTIATIONS AND THEIR TIMING.  Full Article

Recordati Q1 Net Profit Up At EUR 86.6 Mln
Tuesday, 8 May 2018 

May 8 (Reuters) - Recordati Industria Chimica e Farmaceutica SpA ::Q1 REVENUE EUR 366.5 MILLION VERSUS EUR 341.9 MILLION YEAR AGO.Q1 NET PROFIT EUR 86.6 MILLION VERSUS EUR 78.5 MILLION YEAR AGO.CONFIRMS 2018 TARGETS.  Full Article

Recordati Q3 net profit up at EUR ‍​72.8 mln, confirms FY targets
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - RECORDATI ::Q3 NET PROFIT EUR ‍​72.8 MILLION VERSUS EUR 59.6 MILLION YEAR AGO.Q3 REVENUE EUR 313.0 ‍​MILLION VERSUS EUR 274.5 MILLION YEAR AGO.INTERIM 2017 DIVIDEND OF EUR 0.42 PER SHARE TO BE DISTRIBUTED‍​.CONFIRMS FY 2017 TARGETS.  Full Article

Recordati: European Commission approves Reagila as schizophrenia treatment
Wednesday, 19 Jul 2017 

July 19 (Reuters) - RECORDATI SPA ::EUROPEAN COMMISSION APPROVES REAGILA (CARIPRAZINE) FOR TREATMENT OF SCHIZOPHRENIA.  Full Article

Recordati signs license agreement with Richter to commercialize cariprazine
Tuesday, 2 Aug 2016 

Recordati Industria Chimica e Farmaceutica SpA : Signs a license agreement with Gedeon Richter (Richter) to commercialize cariprazine in Western Europe and in Algeria, in Tunisia and in Turkey . The European Medicines Agency (EMA) started the evaluation of Richter's marketing authorization application for cariprazine, an atypical antipsychotic, for the treatment of schizophrenia in March . Recordati to make an upfront payment and further milestone payments depending on the progress of both the regulatory procedure and the product commercialization . Further sales-related royalties will become payable to Richter following the launch of the product .Richter to be responsible for conducting pediatric clinical studies according to the Pediatric Investigation Plan, as required by the European Medicines Agency's PDCO (Pediatric Committee) and it shall be co-financed with Recordati.  Full Article

Recordati H1 net profit jumps at EUR 122.7 mln
Thursday, 28 Jul 2016 

Recordati Industria Chimica E Farmaceutica SpA : H1 net profit 122.7 million euros ($136.07 million) versus 103.2 million euros a year ago, up 18.9 percent .H1 net revenues 587.9 million euros versus 539.1 million euros a year ago, up 9.1 percent.  Full Article

Recordati buys 100 pct stake in Swiss pharmaceutical company Pro Farma
Thursday, 14 Jul 2016 

Recordati Industria Chimica e Farmaceutica SpA : Announces acquisition of 100 percent of share capital of Pro Farma AG, a swiss pharmaceutical company .Value of transaction (enterprise value) is of 16 million Swiss francs ($16.31 million) and will be funded from existing liquidity.  Full Article